Inflammasome activation has been documented in COVID-19 patients with cardiac involvement, as shown by increased plasma levels of inflammasome markers including IL-1β, IL-1R antagonist (IL-1RA), IL-18 and IL-18-binding protein (IL-18BP) (127). This evidence concerns the gene IL18 and COVID-19.